On May 29, METiS Pharmaceuticals-P fell 5.08% in regular trading, trading at HK$15.31 per share, with trading volume of HK$17.89 million.

On the news front, METiS Pharmaceuticals, known as the world's first AI drug delivery company to go public, listed on the Hong Kong Stock Exchange on May 13 at an IPO price of HK$10.50 and surged 173% on its debut. However, the stock has been in sustained retreat over multiple consecutive trading sessions since listing, pulling back significantly from its first-day high.

The company remains in the early stages of commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue, leaving its growth outlook uncertain. Additionally, some internationally placed shares carry no lock-up period, generating persistent profit-taking pressure. Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to co-develop next-generation in vivo protein therapeutics and immunotherapies, post-IPO market enthusiasm continues to cool rapidly, sustaining downward pressure on the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)